An Evaluation of the Ability to Train Established Glaucoma Patients Who Have Difficulty in Drop Instillation
NCT01719809 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 18
Last updated 2017-04-12
Summary
This is a prospective, observational, single-center study. Patients with at least 3 months of experience using topical medications for glaucoma and who state that they administer their own eye drops will be recruited. Subjects will be videotaped instilling a sterile artificial eye drop, will be identified at the time of a regularly scheduled exam. If the patient can get a drop onto the eye and also not touch their lids or ocular surface with the eye drop bottle, the subject will be thanked but not enrolled. All other patients who agree to participate will be enrolled. Upon completion of videotaped instillation of an eye drop, each enrolled patient will be shown a video demonstrating an instillation technique and will be given an instructional handout highlighting a proper drop instillation technique. If necessary, an instillation technique will be demonstrated to them by an investigator or trained personnel.
A patient will be identified as properly instilling a drop if they satisfy the following criteia:
They are able to instill one (and only one) drop to the ocular surface or lower fornix without allowing the bottle touch the adnexa, eyelid, eye lashes or eye.
All patients routinely return between 3 and 6 months. At this regularly scheduled visit,the investigator or trained personnel would direct the patient to instill an eye drop into the study eye.Additionally, the short glaucoma self-efficacy questionnaire will be re-administered.
All of the video-recordings of participants' eye drop instillation techniques will be reviewed and assessed using a standard checklist. Their ability to administer an eye drop after training will be compared to baseline.
Conditions
Sponsors & Collaborators
-
Robin, Alan L., M.D.
lead INDIV
Principal Investigators
-
Adam C LePosa, OD · Alan L. Robin, MD, PA
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-10-31
- Primary Completion
- 2015-06-30
- Completion
- 2015-06-01
Countries
- United States
Study Locations
More Related Trials
-
A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension
NCT00051194 ·Status: COMPLETED ·Phase: PHASE2
-
Glaucoma Adherence Study
NCT00676637 ·Status: COMPLETED
-
Safety and Efficacy of a Drug Delivery System in Glaucoma
NCT01016691 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of a Glaucoma Drug Delivery System
NCT00824720 ·Status: COMPLETED ·Phase: PHASE2
-
Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101
NCT02656394 ·Status: COMPLETED ·Phase: PHASE2
-
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance
NCT04412096 ·Status: COMPLETED ·Phase: PHASE4
-
Adherence Improvement in Glaucoma Patients
NCT00603005 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Necessity of Time Interval Between Instillation of Two Glaucoma Eye Drops
NCT03220490 ·Status: UNKNOWN ·Phase: NA
-
A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT00311389 ·Status: COMPLETED ·Phase: PHASE3
-
Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure
NCT01731002 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
NCT00333125 ·Status: COMPLETED ·Phase: PHASE3
-
Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial
NCT05844384 ·Status: RECRUITING ·Phase: NA
-
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
NCT05913232 ·Status: COMPLETED ·Phase: PHASE2
-
24 Hour IOP Lowering Efficacy of AL-3789
NCT00643669 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
NCT03293992 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients
NCT00069706 ·Status: COMPLETED ·Phase: PHASE2
-
Open-Label Study of Safety of H1337 in Healthy Volunteers
NCT06572397 ·Status: COMPLETED ·Phase: PHASE1
-
Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure
NCT01060579 ·Status: COMPLETED ·Phase: PHASE2
-
Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension
NCT01223378 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
NCT00326092 ·Status: COMPLETED ·Phase: PHASE2
-
H-1337 Ophthalmic Solution Phase 1/2
NCT03452033 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
NCT00287521 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
NCT07168902 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty
NCT00567411 ·Status: UNKNOWN ·Phase: NA
-
Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
NCT02136940 ·Status: COMPLETED ·Phase: PHASE2